CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
CANADA

About Us

Conference

Partner With Us

  • APAC
    • US
    • EUROPE
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    Bioinformatics & Genomics
    BioTech
    Cell and Gene Therapy
    Drug Discovery and Development
    Life Science AI
    Next-Generation Sequencing
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    CDMO
    Cosmetic
    CRO
    Life Science Testing And Compliance
    Supplement Manufacturing
  • Business Services
    Life Science Consulting
    Life Sciences Marketing and Communication
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

ASCENT PHARMACEUTICALS, INC.

Cori L. Rizman, Vice President of DEA Compliance, ASCENT PHARMACEUTICALS

Inside DEA Compliance: Risk, Pressure, and Leadership

Cori L. Rizman

Cori L. Rizman

Regulatory Enforcement Voice

What Shaped the Compliance Leadership Approach


I’ve been fortunate to have leaders who modeled consistency, fairness, candor, and most importantly, approachability. Equally impactful were the experiences that showed me what I did not want to carry forward.


Some of the most formative moments came from navigating disappointment, mistakes, and outcomes outside of my control. During my time with DEA, I spent months—sometimes years—building cases, only to have them declined for prosecution despite being viable. It was difficult to accept the fact that effort did not always translate into outcome. That experience strengthened my resilience and reinforced the importance of staying focused on only what I could realistically control.


Working as a young female investigator in a predominantly male environment also shaped my leadership approach. There were moments of doubt—both internal and external—where my capabilities were questioned or my contributions overlooked. Rather than allowing that to define me, I leaned into my integrity and held myself accountable to my own personal standards. In addition to personal and professional growth, this forced me to recognize that my own personal validation was far more valuable than anyone else’s.


Leadership is not about being liked; it’s about being trusted.

 


Today, those experiences drive how I lead. I prioritize transparency, accountability, and doing the right thing—even when it’s difficult. Leadership is not about being liked; it’s about being trusted. That sometimes means having hard conversations or making tough decisions, but those moments ultimately define both the leader and the organization.


Major Compliance Challenges Facing Pharma Today


Two challenges continue to dominate the landscape:


1. DEA Quota Constraints


Controlled substance manufacturers operate within strict DEA quota allocations, which directly limit how much product can be manufactured. When demand shifts or supply disruptions occur, manufacturers are often forced into a reactive posture—seeking additional quota while balancing regulatory scrutiny, supply obligations, and potential shortage impacts.


Regulatory Engagement and Communication


Historically, there has been hesitation within the industry to engage openly with regulators, particularly the DEA, due to concerns of retaliation or reputational damage. Pathways for meaningful, solution-oriented dialogue have not always been clear and could still use improvement today. Bridging that gap remains a critical opportunity for improving both compliance outcomes and patient access.


Balancing Compliance with Operational Efficiency


Coming from a government background, I initially approached compliance in very black-and-white terms. Transitioning to industry required a shift toward risk-based decision-making.


Today, I focus on structured risk assessment—identifying potential risks, evaluating the likelihood of exposure, and understanding the potential impact. Not all risks carry the same weight. In some cases, a financial risk may be more acceptable, while in others, reputational risk is non-negotiable.


Operational efficiency comes from prioritization. It’s not about doing everything at once—it’s about focusing on the areas that matter most, aligning resources accordingly, and making informed, defensible decisions.


Trends Influencing Compliance and Risk Management


Customer due diligence, carrier oversight, and Suspicious Order Monitoring (SOM) continue to be central to compliance strategy.


Organizations are placing increased emphasis on understanding not just their customers, but the full supply chain ecosystem. Ensuring that customers and logistics partners have effective controls in place to prevent diversion is critical. This requires ongoing monitoring, data-driven insights, and a proactive—not reactive—approach to risk.


Building a Career in Regulatory Compliance


For professionals looking to build a career in regulatory compliance, my advice is to lead with integrity and empathy. If you can consistently make decisions that allow you to feel confident and accountable at the end of the day, you’re on the right path.


Compliance is not just about regulations—it’s about judgment, courage, and growth. If you stay grounded in that, your career will take care of itself.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

Regulatory scrutiny across controlled substances is tightening as life sciences organizations confront rising enforcement complexity and cross-border compliance expectations. This perspective underlines how DEA governance is becoming a central operational discipline rather than a back-office legal function in pharmaceutical enterprises.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review APAC
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review APAC. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreviewapac.com/leadership-perspective/cori-l-rizman-nwid-3289.html